The registry also did not systematically record the use of important HF-related medications sodium glucose cotransporter 2 inhibitor, mineralocorticoid receptor antagonists and angiotensin receptor neprilysin inhibitor. This evidence concerns the gene NR3C2 and hydrops fetalis.